Rebuilding consortia for each project risks redundancy of effort and fragmentation.
If you believe in the power of working well together with multiple stakeholders to change the future of medicine, so do we.
We are focused on strengthening the factors that differentiate long term, impactful consortia from more transient consortia that underperform.
We help deploy a well-established and proven process that was developed over 12 years and more than 8.000 hours of multi-stakeholder dialogues in signature collaborative projects such as: U-BIOPRED, AirPROM, COPD MAP, eTRIKS, SHARP CRC, and now AIMS 2 Trials.
Using a design thinking process we help you build models for sustained collaboration that:
- Engage 80% or more of project partners in helping you to deliver
- Have at least 4 X more opportunities for funding
- Make progress 50% faster than a typical collaborative project
- Increase the meaningful involvement of stakeholders, in particular patient stakeholders
- Incorporate transformative technology SMEs to accelerate clinical implementation
It takes nearly 17 years to go from scientific finding to clinical implementation.
We know that by giving proper attention to each partner’s internal priorities, and then working together to integrate those priorities, you can build on project outputs to create new projects where all the partners win.
More importantly those suffering from disease win. It is aligned communities of different stakeholders working in coordinated ecosystems of innovation that make real change happen.
Unable to continue his career as a clinician researcher because of cross border work permitting issues, Scott Wagers founded BioSci Consulting in 2006 as a temporising measure.
It was a struggle. Designing and delivering collaborative projects is very different from conducting your own research. Then the opportunity arose to partner with one of the icons in the field of asthma research, Peter Sterk.
Together with a group of leaders in the field they designed and delivered one of the initial flagship projects of the Innovative medicines initiative: U-BIOPRED.
In addition to U-BIOPRED, at BioSci Consulting we have helped design and deliver a number of paradigm shifting projects across various domains worth more than 178 million euros:
If you would like to make a real difference in medicine with a highly performing project, ....
We would love to hear from you.
An idea is just a beginning, and proof of concept alone does not help patients.
"To him who devotes his life to science, nothing can give more happiness than increasing the number of discoveries, but his cup of joy is full when the results of his studies immediately find practical applications."